<DOC>
	<DOCNO>NCT01538940</DOCNO>
	<brief_summary>This study assess efficacy new intradermal formulation trivalent inactivate influenza vaccine compare standard intramuscular vaccine HIV-infected men sex men Bangkok , Thailand . Relative efficacy two different formulation influenza vaccine assess compare immunologic response vaccine two study arm .</brief_summary>
	<brief_title>Immunogenicity Influenza Vaccines HIV-infected Persons Thailand</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Thai men nationality sex men HIVinfected HIVuninfected men At least 18 year age Willing able provide write informed consent Availability commitment 12 month study followup ( 3 study visit ) Men severe allergy chicken egg ( specifically ask severe egg allergy screen visit ; appendix C1 ) Men &gt; 60 year age Men severe reaction influenza vaccine past Men history GuillainBarr√© Syndrome Men receive influenza vaccine within 12 month prior enrollment Men steroid therapy immunosuppressant medication Men receive vaccine 4 week prior first study visit plan receive vaccine ( influenza vaccine provide study protocol ) 4 week follow first study visit Men receive experimental agent ( vaccine , drug , biologic , device , blood product , medication ) within 1 month prior enrollment study , expect receive experimental agent 12 month study period Men condition , opinion investigator , would place unacceptable risk injury render unable meet requirement protocol . ( e.g. , severe reaction another vaccine , blood clot disorder , inflammatory skin condition ) . Foreign ( nonThai ) nationality</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Thailand</keyword>
</DOC>